A differential protein with m/z 11.6 kDa was detected and identified as an isoform of human serum amyloid A (SAA). It was significantly increased by 1822% in lung cancer patients when compared with the healthy controls.

The blood levels of serum amyloid A protein and transthyretin were found to be significantly increased in lung cancer patients.

Data suggest that a higher concentration of SAA can serve as an indicator of lung adenocarcinoma and represents a therapeutic target for the inhibition of lung cancer metastasis.

report abundance levels of SAA in serum samples from patients with advanced breast cancer, colorectal cancer (CRC) and lung cancer compared to healthy controls (age and gender matched) using commercially available enzyme-linked immunosorbent assay kits

High SAA expression is associated with lung cancer.

SR-A1 suppresses lung cancer metastasis by downregulating SAA1 production in tumor-associated macrophages (TAM).

Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory ""FoRECATT"" study.